Curaleaf has cleared all competition law requirements for its Aurora Cannabis bid, positioning its December 4, 2026, offer as a more certain path to closing compared to the competing Organigram proposal.
Curaleaf has secured all required competition clearances (Germany Oct 20 / Nov 3, Canada Nov 2) for its bid for Aurora, leaving only offer conditions before the December 4, 2026 expiry. This materially reduces deal risk versus the competing Organigram proposal and supports a faster closing, a tangible positive for CURA holders.
All required antitrust clearances for Curaleaf's October 6 enhanced premium bid are now secured, with the offer running to December 4, 2026. Greater certainty of completion and a faster path to closing strengthen the case for Aurora shareholders to tender, supporting the share price toward the offer value.
Curaleaf's competing proposal for Aurora is now fully cleared by competition regulators, while Organigram's proposed acquisition still needs shareholder, court and regulatory approvals. Curaleaf is explicitly telling Aurora shareholders to weigh this advantage, weakening Organigram's competing bid's prospects.
Curaleaf Holdings announced it has received all necessary competition law clearances in Germany and Canada for its proposed acquisition of Aurora Cannabis. With regulatory hurdles cleared, the company aims to highlight the certainty of its enhanced premium bid, which remains open until December 4, 2026. Curaleaf contrasts this progress with the competing Organigram proposal, which still requires further approvals.
That it received competition law clearances in Germany and Canada, the only two jurisdictions where clearance was required, for its proposed acquisition of Aurora Cannabis.
The enhanced premium bid from October 6, 2026 expires on December 4, 2026 unless withdrawn or amended.
Competition law reviews are complete in both Germany and Canada, but the offer still depends on its remaining conditions being satisfied or waived and on shareholder response before the December 4, 2026 expiry.
Curaleaf argues that with all clearances secured its offer offers greater certainty of completion and a faster closing than the competing Organigram proposal.
Curaleaf's acquisition of Aurora has all competition clearances, while Organigram's competing proposed acquisition still requires shareholder, court and regulatory approvals, making its bid comparatively less certain.